Shield
Guardant Health, Inc. · Decision date Feb 4, 2026
What did the FDA decide?
FDA records P230009/S013 as a supplement to PMA P230009, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 4, 2026.
FDA approval order statement
creation of a new part number
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Medical Genetics
- Decision date
- Feb 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230009/S013
- Regulatory pathway
- PMA supplement
- Applicant
- Guardant Health, Inc.
- Product code
- PHP
- Decision code
- OK30
- Decision date
- Feb 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.
- Applicant
- Guardant Health, Inc.
- Product code
- PHP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230009 · Original PMA
Shield
P230009/S013 received
Application receipt date recorded by FDA.
P230009/S013 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ShieldP230009 | Guardant Health, Inc. | PMA approval | Jul 26, 2024 | FDA |
ShieldP230009/S007 | Guardant Health, Inc. | PMA supplement | Jul 23, 2025 | FDA |
ShieldP230009/S008 | Guardant Health, Inc. | PMA supplement | Sep 23, 2025 | FDA |
ShieldP230009/S009 | Guardant Health, Inc. | PMA supplement | Oct 30, 2025 | FDA |
ShieldP230009/S011 | Guardant Health, Inc. | PMA supplement | Dec 22, 2025 | FDA |
ShieldP230009/S015 | Guardant Health, Inc. | PMA supplement | Apr 1, 2026 | FDA |
ShieldP230009/S014 | Guardant Health, Inc. | PMA supplement | Apr 15, 2026 | FDA |
ShieldP230009/S016 | Guardant Health, Inc. | PMA supplement | May 21, 2026 | FDA |
ShieldP230009/S018 | Guardant Health, Inc. | PMA supplement | Jul 21, 2026 | FDA |
ShieldP230009/S010 | Guardant Health, Inc. | PMA supplement | Jul 22, 2026 | FDA |
ShieldP230009/S020 | Guardant Health, Inc. | PMA supplement | Sep 16, 2026 | FDA |
ShieldP230009/S021 | Guardant Health, Inc. | PMA supplement | Oct 5, 2026 | FDA |
Explore the linked device profile
Other records with product code PHP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SimpleScreen CRCP250029/S003 | Freenome, LLC | PMA supplement | Oct 27, 2026 | FDA |
SimpleScreen CRCP250029/S001 | Freenome, LLC | PMA supplement | Aug 26, 2026 | FDA |
Cologuard PlusP230043/S010 | Exact Sciences Corporation | PMA supplement | Aug 3, 2026 | FDA |
SimpleScreen CRCP250029 | Freenome, LLC | PMA approval | Jul 24, 2026 | FDA |
CologuardP130017/S070 | Exact Sciences Corporation | PMA supplement | Jun 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Guardant Health, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3000 Hanover St., Palo Alto, CA, 94304
Sources and methodology
- Original FDA record: P230009/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





